Verizon Communications Inc vs GeneDx Holdings Corp — how do they compare? Verizon Communications Inc trades at $43.74 (market cap $181.64B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Verizon Communications Inc is far larger — about 100.9× GeneDx Holdings Corp's market cap, and Verizon Communications Inc pays a 6.51% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| VZ | WGS | |
|---|---|---|
Market Cap | $181.64B | $1.80B |
Volume | 22,584,735 | — |
Sector | Media | Technology |
52-Week High | $51.38 | $167.51 |
52-Week Low | $38.40 | $34.51 |
Enterprise Value | $369.14B | $1.80B |
Dividend Yield | 6.51% | — |
Signals from Pluang's Aura AI — not financial advice
Verizon (VZ) trades at $43.78, up 0.44% today, with a bearish technical signal but strong fundamentals including a P/E of 10.61 and consistent earnings beats. Recent news highlights a restructuring involving 3,000 job cuts and the sale of 274 stores to franchisees, aimed at boosting efficiency ahead of Q2 2026 earnings. Cash flow improved in 2025 with net cash flow of $14.9 billion, supporting its 6.5% dividend yield.
Outlook: Attractive for income investors due to stable cash flows and high dividend, but faces risks from 5G competition and margin pressure. Analyst consensus price target is $47.83, suggesting upside potential if execution improves. Key risks include debt levels and industry discounts threatening profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →